All In Biotech

NDA 211651 · Pfizer

Talzenna

Talazoparib Tosylate · Oral

NovelPriority reviewDiscontinued

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Oct 16, 2018

Approved uses

8

Original approval plus efficacy supplements

Registered trials

108

5 Phase 3, 25 recruiting

FAERS reports

1,853

1,494 serious, 342 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 28, 2026.

TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: Breast Cancer • As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-authorized companion diagnostic for TALZENNA. ( 1.1 , 2.1 ) Prostate Cancer In combination with enzalutamide for the treatment of adult patients with: • metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test. ( 1.2 , 2.1 ) • metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with HRR gene mutations, as detected by an FDA-authorized test. ( 1.2 , 2.1 ) 1.1 BRCA -mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene ( BRCA )-mutated (g BRCA m) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-authorized companion diagnostic for TALZENNA [see Dosage and Administration (2.1) ] . 1.2 HRR Gene-Mutated Metastatic Prostate Cancer TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with: • metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] . • metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with HRR gene...

Mechanism: Talazoparib is an inhibitor of PARP enzymes, including PARP1 and PARP2, which play a role in DNA repair. In vitro studies with cancer cell lines that harbored defects in DNA repair genes, including BRCA1 and BRCA2 , have shown that talazoparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, decreased cell proliferation, and apoptosis. Talazoparib anti-tumor activity was observed in patient-derived xenograft breast cancer models bearing mutated BRCA1 or mutated BRCA2 or wild type BRCA1 and BRCA2 .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 26, 2026 Supplement 14 · Efficacy · priority review LabelLetter
  • Jun 12, 2025 Supplement 13 · Efficacy · priority review LabelLetter
  • Jun 20, 2023 Supplement 10 · Efficacy · priority review LabelLetter
  • Sep 9, 2021 Supplement 7 · Efficacy LabelLetter
  • Oct 22, 2020 Supplement 6 · Efficacy LetterLabel
  • Mar 9, 2020 Supplement 5 · Efficacy LetterLabel
  • Sep 24, 2019 Supplement 2 · Efficacy LabelLetter
  • Oct 16, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
6 products under this application
  • TALZENNA · TALAZOPARIB TOSYLATE EQ 0.1MG BASE · CAPSULE, ORAL · Discontinued
  • TALZENNA · TALAZOPARIB TOSYLATE EQ 0.5MG BASE · CAPSULE, ORAL · Discontinued
  • TALZENNA · TALAZOPARIB TOSYLATE EQ 0.25MG BASE · CAPSULE, ORAL · Discontinued
  • TALZENNA · TALAZOPARIB TOSYLATE EQ 0.35MG BASE · CAPSULE, ORAL · Discontinued
  • TALZENNA · TALAZOPARIB TOSYLATE EQ 0.75MG BASE · CAPSULE, ORAL · Discontinued
  • TALZENNA · TALAZOPARIB TOSYLATE EQ 1MG BASE · CAPSULE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Talazoparib" as an intervention, any sponsor and status, largest first.

All 108 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaemia285
  • death194
  • neoplasm progression171
  • fatigue137
  • off label use101
  • thrombocytopenia100
  • haemoglobin decreased85
  • malignant neoplasm progression80
  • platelet count decreased79
  • febrile neutropenia71
  • pancytopenia71
  • nausea67

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20155
20162
201721
201829
2019210
2020202
2021154
2022199
2023252
2024239
2025336
2026204

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Talzenna (Talazoparib Tosylate)

2024 spending

$59.8M

Beneficiaries

790

3,741 claims

Per beneficiary

$75,749

$520.34 per unit

View as table
YearSpending
2020$8,270,787
2021$7,758,691
2022$6,401,237
2023$14,816,664
2024$59,841,806

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 90 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.